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of neurite-like processes on breast cancer cells and promotes
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Voltage-gated Na1 channels (VGSCs) are heteromeric proteins composed of pore-forming a subunits and smaller b subunits.
The b subunits are multifunctional channel modulators and are members of the immunoglobulin superfamily of cell adhesion
molecules (CAMs). b1, encoded by SCN1B, is best characterized in the central nervous system (CNS), where it plays a critical
role in regulating electrical excitability, neurite outgrowth and migration during development. b1 is also expressed in breast
cancer (BCa) cell lines, where it regulates adhesion and migration in vitro. In the present study, we found that SCN1B mRNA/
b1 protein were up-regulated in BCa specimens, compared with normal breast tissue. b1 upregulation substantially increased
tumour growth and metastasis in a xenograft model of BCa. b1 over-expression also increased vascularization and reduced
apoptosis in the primary tumours, and b1 over-expressing tumour cells had an elongate morphology. In vitro, b1 potentiated
outgrowth of processes from BCa cells co-cultured with fibroblasts, via trans-homophilic adhesion. b1-mediated process out-
growth in BCa cells required the presence and activity of fyn kinase, and Na1 current, thus replicating the mechanism by
which b1 regulates neurite outgrowth in CNS neurons. We conclude that when present in breast tumours, b1 enhances patho-
logical growth and cellular dissemination. This study is the first demonstration of a functional role for b1 in tumour growth
and metastasis in vivo. We propose that b1 warrants further study as a potential biomarker and targeting b1-mediated adhe-
sion interactions may have value as a novel anti-cancer therapy.
Although the death rate from breast cancer (BCa) is falling
in many countries, it is still the leading cause of cancer-
related deaths in women, due to metastasis.1,2 To metastasize,
tumour cells undergo a complex sequence of events, includ-
ing adhesion/detachment, migration, and invasion. Given
that treatment options for metastatic BCa are mainly
restricted to palliation, it is necessary to better understand
the mechanism(s) involved in order to identify new targets
and develop new therapies.3
Voltage-gated Na1 channels (VGSCs) contain one pore-
forming a subunit with smaller b subunits.4 There are nine
a subunits, Nav1.1-Nav1.9, and four b subunits, b1-b4. The
b subunits are members of the immunoglobulin superfamily
of cell adhesion molecules (CAMs). They modulate channel
gating, and can function as CAMs both in the presence and
absence of a subunits.5 They are substrates for secretase
cleavage, releasing soluble intracellular domains that may reg-
ulate gene expression.6 The b1 subunit (gene: SCN1B) partic-
ipates in trans-homophilic adhesion, resulting in cellular
aggregation and cytoskeleton recruitment.7,8 b1 also interacts
heterophilically with other CAMs, including b2, contactin,
neurofascins, NrCAM, N-cadherin9–12 and the extracellular
matrix protein, tenascin-R.13 b1 mediates neurite outgrowth
by a trans-homophilic adhesion mechanism that requires fyn
kinase, contactin and g-secretase activity.5,14,15 b1 plays a
critical role during central nervous system (CNS) develop-
ment, regulating electrical excitability, proliferation, fascicula-
tion, pathﬁnding and migration.15–17
VGSCs are widely expressed in cancers, and contribute to
cellular behaviours associated with metastasis.18,19 In BCa,
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the predominant a subunit, Nav1.5 (gene: SCN5A), is
expressed in MDA-MB-231 cells, where Na1 current potenti-
ates invasion by enhancing cysteine cathepsin activity.20–22
SCN5A is up-regulated in tumours, associating with recur-
rence, metastasis and reduced survival.20,23 b1 is the predom-
inant b subunit in MCF-7 cells, where it enhances
cell-substrate adhesion, but slows transwell migration.24
Over-expression of b1 in MDA-MB-231 cells increases cell-
cell adhesion and Na1 current.24 Both a and b1 subunits are
expressed in lamellipodia of MCF-7 and MDA-MB-231 cells,
suggesting that their expression and function are not mutu-
ally exclusive.23 Thus, VGSC a and b subunits appear to
play complex, dynamic roles in metastatic BCa cells. How-
ever, the functional signiﬁcance of b1-dependent adhesion,
and its contribution to tumour growth and metastasis, are
unknown.
Our aim here was to study the involvement of b1 in BCa
progression in vivo. We show that SCN1B mRNA/b1 protein
are upregulated in BCa specimens, compared with normal
breast tissue. Up-regulation of b1 potentiates tumour growth
and metastasis in vivo. In addition, b1 increases process out-
growth on BCa cells via a trans-homophilic adhesion mecha-
nism that requires fyn kinase and Na1 current. We propose
that b1 enhances metastatic behaviour of BCa cells by reca-
pitulating mechanism(s) that are critical for neuronal migra-
tion during CNS development. These ﬁndings suggest that
b1 warrants further study as a potential biomarker/therapeu-
tic target.
Methods
In silico analysis
SCN1B expression in microarrays was studied using Onco-
mine.25 Meta-analysis of correlations between SCN1B expression
and histoclinical characteristics across multiple datasets was as
described.26 Datasets, patients, specimen characteristics and
assay methods are detailed/referenced at www.oncomine.org.
Cell culture
Molecular identity of all BCa cell lines was conﬁrmed by
short tandem repeat analysis. All cell lines were grown in
Dulbecco’s modiﬁed eagle medium (DMEM) supplemented
with 5% fetal bovine serum and 4 mM L-glutamine.23 BT474
and SKBR3 cells were a gift from J. Rae, University of Michi-
gan. MCF-7 and MDA-MB-231 cells were a gift from
M. Djamgoz, Imperial College London. “Control” MDA-MB-
231 cells stably expressing enhanced green ﬂuorescent protein
(GFP) or MDA-MB-231 cells over-expressing b1-GFP C-
terminal fusion24 (hereafter called “MDA-MB-231-b1” cells)
were maintained in medium containing selective antibiotics.
MCF-10A cells were a gift from N. Maitland, University of
York. R1610 Chinese hamster lung (CHL) ﬁbroblasts and
CHL ﬁbroblasts stably expressing b1 were gifts from L. Isom,
University of Michigan. MDA-MB-231-GFP and MDA-MB-
231 b1-GFP cells were stably transduced with recombinant
lentivirus for ﬁreﬂy luciferase (AMS Biotechnology). For
experiments using estrogen, MCF-7 cells were maintained in
phenol red-free DMEM supplemented with 5% charcoal-
stripped fetal bovine serum and 4 mM L-glutamine. Cells
were conﬁrmed as mycoplasma-free using the DAPI method.
Pharmacology
Tetrodotoxin (TTX) was diluted in culture medium to 30
mM. Staurosporine, PP2, estradiol and fulvestrant were pre-
pared as stocks in DMSO and then diluted in culture
medium to 10 nM230 mM. In assays that exceeded 24 h,
treatments were replaced daily. The effect of TTX on inva-
sion was determined using Matrigel assays.23 The effect of
staurosporine on apoptosis was determined using DeadEnd
ﬂuorometric TUNEL assays (Promega). The effect of PP2 on
cell viability and proliferation was determined using trypan
blue and MTT assays.23
RNA isolation and RT-qPCR
RNA extraction and cDNA synthesis were as described.27
QPCR was carried out using triplicate 12-ml reactions con-
taining 20ng cDNA. Ampliﬁcation conditions were: 95C for
30 s followed by 35 cycles of 95C for 5 s and 60C for 10 s
on a Bio-Rad thermal cycler. Relative gene expression was
quantitated using the comparative CT method. Primers are in
Supporting Information Table S1.
Patient tissue samples
The study cohort contained tissue samples from 66 BCa cases
obtained from the Breast Cancer Campaign Tissue Bank
under tissue request number TR000017. Patients provided
consent to the Breast Cancer Campaign Tissue Bank for their
tissues to be used for research. The samples came from
women aged 28–89 years, who were diagnosed between
What’s new?
Voltage-gated sodium channels are best known to regulate electrical excitability and neuronal migration, but recently their b1
subunits were found expressed in breast cancer cell lines where they regulate cellular adhesion and migration. Here, the
authors demonstrate that b1 subunits are expressed in clinical breast cancer specimens. In coculture experiments, b1
enhanced outgrowth of neurite-like processes on cancer cells and in in vivo models, accelerated tumor growth and metastasis.
These data underscore the new role of voltage-gated sodium channel b1 subunits as potential biomarkers and therapeutic
targets in breast cancer.
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February 1992 and February 2012. For 40 cases (60%),
tumour samples came with matched surrounding normal
breast tissue. Clinical and histopathological data were avail-
able for all cases. Immunohistochemistry was performed on
5mm-thick sections using the EnVision1 System-HRP kit
(Dako). Sections were deparafﬁnized in Histo-Clear (National
Diagnostics) followed by antigen retrieval at 95C for 30 min
in Target Retrieval Solution (Dako). Sections were incubated
with anti-b1 antibody (1:25; Abgent) for 30 mins and coun-
terstained with dilute Mayer’s hematoxylin and mounted in
Faramount medium (Dako). Slides were scanned at 403
using an Aperio ScanScope. b1 immunoreactivity was scored
by two independent investigators (WJB and RMS, a breast
histopathologist) using the Allred method.28 Brieﬂy, the pro-
portion of b1-positive cells was given a score (none: 0; <1/
100: 1; 1/100 to 1/10: 2; 1/10 to 1/3: 3; 1/3 to 2/3: 4; >2/3:
5), followed by the intensity of staining (none: 0; weak: 1;
intermediate: 2; strong: 3). For each section, the proportion
and intensity scores were summed to give a total score (0–8).
A score of 0–4 was considered “low” and 5–8 was considered
“high.” Scoring was performed without prior knowledge of
outcome data. Experiments were approved by the University
of York Ethical Review Process.
Western blotting
SDS-PAGE was performed as described.15,29 The following
antibodies were used: rabbit anti-b1 (1:100; Abgent), mouse
anti-fyn (1:1,000; BioLegend), mouse anti-CD44 (1:1,000;
AbD Serotec); rabbit anti-E-cadherin (1:1,000; Cell Signaling
Technology); mouse anti-b-actin (1:30,000; Proteintech); and
mouse anti-a-tubulin (1:10,000; Sigma). Signals were quanti-
ﬁed using ImageJ software. a-tubulin was used as loading
control.
Orthotopic breast tumour model
All animal procedures were carried out after approval by
the University of York Ethical Review Process and under
authority of a UK Home Ofﬁce Project Licence. Six-week-
old female Rag22/2 Il2rg2/2 mice (mean weight: 16.66
0.2 g) were obtained from the Yorkshire Cancer Research
Unit, University of York. Mice (4–5 per speciﬁc pathogen
free cage) were selected at random for surgery. A 1 3 106
control MDA-MB-231-GFP or MDA-MB-231-b1-GFP cells
expressing luciferase were suspended in Matrigel (20% v/v
in saline) and injected into the left and right inguinal
mammary fat pad of each animal whilst under isoﬂurane
anaesthesia. A total of 13 mice were used (six injected with
control cells and seven with b1 cells) across three inde-
pendent replicated experiments. Tumour growth was
monitored weekly by bioluminescence imaging. Mice were
given intraperitoneal injection of D-luciferin in PBS (150
mg kg21) and bioluminescence was visualized 10 min later
under isoﬂurane anaesthesia using an IVIS100 system (Per-
kinElmer). Bioluminescence from tumours was quantiﬁed
within manually deﬁned regions of interest using Living
Image software (PerkinElmer) and expressed as photon
ﬂux. To quantify bioluminescence at sites of metastasis,
mice were euthanized 10 min after injection with
D-luciferin, primary tumours were removed and internal
organs were exposed by dissection. Bioluminescence was
measured from the entire mouse and then individual
organs were removed for separate imaging. Measurements
of the length and width of each tumour (in mm) were
taken from mice daily with callipers. Tumour volume was
calculated as 0.5 3 (length 3 width2). Mice were eutha-
nized when primary tumours reached 10% of starting body
weight, or at the ﬁrst sign of discomfort from metastatic
burden. Tumours and organ sites of metastasis were ﬁxed
in 4% paraformaldehyde and frozen.14
Immunohistochemistry (IHC) and immunocytochemistry
(ICC)
For H&E staining, sections were stained with Gill’s hema-
toxylin and eosin Y and then scanned at 20X using a Zeiss
AxioScan.Z1 slide scanner. The following primary antibod-
ies were used for IHC/ICC15: rabbit anti-Ki67 (1:5,000;
Abcam); rabbit anti-activated caspase-3 (1:200; R&D Sys-
tems); rabbit anti-CD31 (Santa Cruz Biotechnology);
mouse anti-skeletal myosin (1:400; Sigma); rabbit anti-b1
(1:200; Abgent); mouse anti-fyn (1:100; BioLegend); mouse
anti-CD44 (1:100; AbD Serotec); rabbit anti-E-cadherin
(1:200; Cell Signaling Technology); mouse anti-human
nuclear antigen (HNA; 1:100; Millipore). Secondary anti-
bodies were Alexa-568-conjugated goat anti mouse/rabbit,
unless stated otherwise (1:500; Invitrogen). Samples were
mounted in Prolong Gold with DAPI (Invitrogen). Some
samples were stained with Alexa-633-phalloidin (1:25; Invi-
trogen).23 Samples were viewed using 203 objectives on a
Nikon Eclipse TE200 ﬂuorescent microscope, or Zeiss Axio
Observer.Z1 microscope with LSM 710 confocal laser
scanner.
Image analysis
Images were exported into ImageJ for processing. Confocal
Z-series projections were ﬂattened using the maximum signal.
Brightness/contrast was adjusted using the ImageJ “Auto”
function. ICC colocalization was evaluated using ImageJ.
Intensity correlation analysis (ICA) was performed on indi-
vidual cells delineated with the freehand selection tool, and
for each cell, the intensity correlation quotient (ICQ) was
computed. For signal intensities that vary together, indicating
colocalization, 0< ICQ 0.5, whereas for segregated staining,
20.5 ICQ< 0.30 Measurements were from 20 cells per line.
The following measurements were made on IHC sections,
for three mice per treatment group:
 Density of Ki671 or activated caspase-31 cells17: the num-
ber of Ki671 nuclei or active caspase-31 cells was counted
per 20X ﬁeld of view.
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 Tumour vascularity31: the number of CD311 vessels was
counted per 20X ﬁeld of view.
 Metastasis to liver/lungs/spleen32: the number of GFP1
metastatic foci was counted per 20X ﬁeld of view.
 Length of tumour cell processes and muscle ﬁbers: The
longest visible process on cancer cells and the total length
of individual muscle ﬁbers within 203 ﬁelds of view was
measured using the freeform line function in ImageJ.
Figure 1. b1 mRNA and protein expression in breast cancer. (a) Expression of SCN1B mRNA in invasive lobular breast carcinoma (ILBCa) vs.
normal in the Radvanyi Breast dataset (n515). (b) Expression of SCN1B in invasive ductal breast cancer (IDBCa) and ILBCa in the Turash-
vili Breast dataset (n530). Box plot dots, maximum and minimum values; whiskers, 90th and 10th percentile values; and horizontal lines,
75th, 50th, and 25th percentile values. (c) Representative images of non-cancer breast tissue and (d) breast tumour tissue in which b1
was (i) absent, (ii) weakly positive, and (iii) strongly positive. Scale bar, 100 mm. Insets, higher magnification images of tumour cells, scale
bar, 50mm. (e) Mean Allred score for normal breast and tumour samples. Data are mean6SEM (n566). (f) Kaplan–Meier analysis compar-
ing BCa-specific survival of those with “low” (score <5) vs. “high” (score5) b1 expression (n562). (g) Western blot of b1 and fyn in the
MCF-10A non-cancer mammary epithelial cell line. (h) Western blot of b1 and fyn across a panel of BCa cell lines. Positive control5 rat
brain lysate. *p<0.05; **p<0.01; ***p<0.001.
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VEGF ELISA
Cells were cultured in 24-well plates (5 3 104/well). After 1,
2, and 3 days, culture medium was removed from individual
wells and stored at 220C until analysis. VEGF secretion
was determined by ELISA (Promega). Measurements were
obtained from duplicate wells from three repeat experiments.
Process outgrowth assay
Process outgrowth assays were based on Ref. 14. Parental
CHL ﬁbroblasts or CHL ﬁbroblasts expressing b1 were
grown to conﬂuence on 13mm diameter coverslips. Freshly
dissociated BCa cells were plated (2 3 104 cells/well) on top
of the monolayers and allowed to grow for 24–48 h. Cultures
were ﬁxed in 4% paraformaldehyde and the cancer cells were
visualized with anti-GFP (1:1,000; NeuroMab), or anti-
cytokeratin 18 (1:500; BioLegend) followed by Alexa-568-
conjugated goat anti-mouse (1:500). Images were acquired
using a Nikon Eclipse TE200 ﬂuorescent microscope with
403 objective. The longest process on each of the ﬁrst 50
randomly selected, isolated cancer cells was measured using
ImageJ. Measurements were obtained from three independent
experiments.
Deletion of b1 Ig domain
The Ig domain of b1 (amino acids 40–124) in pEGFPN124
was deleted using the Phusion site-directed mutagenesis kit
(Thermo Scientiﬁc). The b1D40–124-GFP construct was
sequenced, and then transfected into MDA-MB-231 cells
using Fugene (Roche).24
RNA interference
SiGENOME SMARTpool siRNA targeting FYN and siGE-
NOME Non-Targeting siRNA Pool #1 (Dharmacon) were
used at 50 nM. Transfection was performed using Dharma-
fect 1 reagent. Transfection efﬁciency was conﬁrmed to be
90% using siGENOME positive control targeting GAPDH
(Supporting Information Fig. S5c). RNA extraction and pro-
cess outgrowth assay were performed 96h after transfection.
Data analysis
Data are mean and SEM unless stated otherwise. Statistical
analysis was performed using GraphPad Prism. Matrix data
were plotted using Matrix2png software.33 Statistical signiﬁ-
cance was determined with t tests or Mann–Whitney tests,
and multiple comparisons were made using ANOVA and
Tukey post hoc tests, unless stated otherwise. p values com-
puted by Oncomine were corrected for multiple comparisons
by Bonferroni method. Correlation between ESR1 and SCN1B
expression was determined using Pearson’s r test. Association
between categorical classiﬁcation criteria was determined
with Fisher’s exact test, or v2 test. For meta-analysis of asso-
ciation between SCN1B expression and histoclinical charac-
teristics across multiple datasets, the binomial test was
used.26 The binomial test p value indicates whether or not
one criterion was associated with another in the observed
number of datasets by chance, given the number of datasets
studied. Kaplan–Meier curves for survival were compared by
log-rank tests. Percent survival and hazard ratios are pre-
sented with 95% conﬁdence intervals. Results were consid-
ered signiﬁcant at p< 0.05.
Results
b1 mRNA and protein are present in breast tumours
We have previously shown that b1 mRNA/protein are
expressed in BCa cell lines.24 Here, we used Oncomine to
study the expression of SCN1B mRNA in normal breast and
BCa specimens across multiple microarrays. SCN1B was
expressed at a signiﬁcantly higher level in BCa compared
with normal breast in two out of eight datasets in which dif-
ferential data were available (1.7-fold, p< 0.05; and >2.2-
fold, p< 0.05; Figs. 1a and 1b). We next performed a meta-
analysis to investigate whether SCN1B expression correlates
with histoclinical characteristics across multiple datasets.
High SCN1B expression associated with ER status in 8/21
(38.1%) of datasets (p< 0.0001; Supporting Information
Table S2; Figs. S1a and S1b). There was no signiﬁcant associ-
ation between SCN1B and age, pathological tumour size,
grade, recurrence, progesterone receptor, or HER2 status
across the same datasets. Up-regulation of SCN1B expression
in ER1 tumours correlated with several genomic neighbours
on chromosome 19q (Supporting Information Fig. S1c).26
However, mRNA levels of the two SCN1B splice variants, b1
and b1B,34 which are both expressed across a panel of BCa
cell lines (Supporting Information Figs. S1d and S1e), were
unchanged in MCF-7 cells following treatment with estrogen
or fulvestrant (Supporting Information Fig. S1f), suggesting
that SCN1B is not estrogen-regulated.
We next studied the expression of b1 at protein level in
human tissue samples by IHC. b1 immunoreactivity was
mainly in the cytoplasm of epithelial and carcinoma cells,
with variable expression at the plasma membrane (Figs. 1c
and 1d). This pattern of expression is consistent with previ-
ous observations in neurons and cancer cell lines.14,16,23 b1
expression was signiﬁcantly higher in tumour than normal,
non-cancer breast tissue samples (p< 0.001; Fig. 1e). Of the
cases where tumour had matched surrounding non-cancer
tissue, 27 (68%) had higher b1 in tumour than non-cancer
tissue, 7 (17%) had the same level of b1 in tumour and non-
cancer tissue, and 6 (15%) had lower expression in tumour
than non-cancer tissue. b1 expression in the tumour did not
correlate with age, ER status, grade, menopausal status, or
node status (Supporting Information Table S3). Similarly,
there was no relationship with BCa-speciﬁc survival (Fig. 1f,
Supporting Information Table S3). In agreement with the
IHC data, b1 was also expressed at protein level in the non-
cancer mammary epithelial MCF-10A cell line and across a
panel of BCa cell lines (Figs. 1g and 1h). Together, these data
suggest that b1 may be up-regulated in a unique subset of
breast cancers at mRNA and protein level.
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b1 promotes tumour growth and vascularization
We next investigated the role of b1 in tumour growth and
metastasis. We orthotopically implanted luciferase-expressing
MDA-MB-231 or MDA-MB-231-b1 cells into the mammary
fat pads of female Rag22/2 Il2rg2/2 mice and monitored
tumour growth by bioluminescent imaging. We chose this
model because MDA-MB-231 cells rapidly form palpable
tumours following orthotopic implantation, and the cells
readily metastasise. MDA-MB-231 cells express very low
endogenous b1 (Supporting Information Fig. S2a). By con-
trast, MDA-MB-231-b1 cells over-express b1-GFP by >40-
fold relative to endogenous b1 (Supporting Information Figs.
S2a and S2b).24 Over-expression of b1 had no effect on
expression of CD44 or E-cadherin (Supporting Information
Figure 2. Effect of b1 over-expression on breast tumour growth in vivo. MDA-MB-231 (“Control”) and MDA-MB-231-b1 (“b1”) cells were
implanted into the inguinal mammary fat pads of female Rag22/2 Il2rg2/2 mice. (a) Representative bioluminescent images of mice bearing
control and b1 tumours, 4 weeks after implantation. (b) Bioluminescence measured from primary tumours on the indicated days post-
implantation (n12). Data are mean6SEM; **p<0.01. (c) Calculated volume derived from calliper measurement of primary tumours over
the same period (n12). (d) Percentage of mice whose primary tumour burden reached 10% of starting body weight within the 5-week
tumour growth period is shown for control and b1 tumours. (e) Kaplan–Meier analysis comparing overall survival of mice bearing control
and b1 tumours (n513). (f) Images of control and b1 tumour tissue sections stained with H&E showing (i) mammary fat pad and (ii) skele-
tal muscle invasion. Arrows, infiltration of tumour cells (T) into fibroadipose tissue (F) or skeletal muscle fibers (M). Scale bar, 100 mm.
Insets, higher magnification images of invading tumour cells, scale bar, 50 mm. (G) Invasion of control MDA-MB-231 and MDA-MB-231-b1
cells6 TTX (30 mM) for 48 hr (n512; *p<0.05; Neuman–Keuls test).
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Figs. S2c–S2e). Importantly, luciferase activity and GFP
expression were very similar in both cell lines (Supporting
Information Figs. S3a–S3d). Photon ﬂux from MDA-MB-
231-b1 tumours increased faster than control MDA-MB-231
tumours, becoming statistically signiﬁcant after 4 weeks (Figs.
2a and 2b). To conﬁrm the bioluminescent imaging data, we
also analyzed tumour growth by daily calliper measurement.
The volume of MDA-MB-231-b1 tumours increased more
rapidly than MDA-MB-231 tumours, closely agreeing with
the bioluminescent data (Fig. 2c). During the 5-week study
period, MDA-MB-231-b1 primary tumour burden reached
10% of starting body weight in 71% of mice, compared with
only 17% for control tumours (Fig. 2d). The survival of mice
bearing MDA-MB-231-b1 tumours was signiﬁcantly reduced
compared to those bearing control tumours (p< 0.05; hazard
ratio5 6.3 [1.4–27.8]; Fig. 2e). These data demonstrate that
Figure 3. Effect of b1 upregulation on proliferation, apoptosis and angiogenesis. (a) Control and b1 tumour sections stained with anti-Ki67
(red) and DAPI (blue). Scale bar, 20 mm. (b) Ki67-positive nuclei per field of view for control and b1 tumours (n530). (c) Control and b1
tumour sections stained with anti-activated caspase-3 (red) and DAPI (blue). Scale bar, 20 mm. (d) Activated caspase-3-positive cells per
field of view for control and b1 tumours (n530). (e) Images of control and MDA-MB-231-b1 cells treated for 24 hr with/without 0.5 mM
staurosporine, analyzed by TUNEL assay (red), counterstained with DAPI (blue). Scale bar, 100 mm. (f) Proportion (%) of TUNEL-positive
nuclei per field of view (n560). (g) Blood vessels stained with endothelial marker CD31 (red) and DAPI (blue) in control and b1 tumour
sections. Scale bar, 20 mm. (h) CD31-positive blood vessels per field of view for control and b1 tumours (n530). (i) VEGF content of cul-
ture medium of control and MDA-MB-231-b1 cells 1–3 days after plating (n56). Data are mean6SEM; **p<0.01; ***p<0.001.
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over-expression of b1 enhanced the growth of breast
tumours, thus reducing survival.
We next studied the structure and composition of the pri-
mary tumours. Both MDA-MB-231 and MDA-MB-231-b1
tumours were broadly similar, containing some invasion into
surrounding ﬁbroadipose tissue and skeletal muscle (Fig. 2f).
Although the in vitro invasiveness of MDA-MB-231-b1 cells
was moderately higher than control MDA-MB-231 cells,
blockade of a subunits with TTX inhibited invasion of both
cell lines to a similar extent (p< 0.05, Fig. 2g). Thus, a-
subunit-dependent invasion of MDA-MB-231 cells20,21
appears to be unaffected by b1 over-expression. The density
of Ki671 cycling cells was unchanged in MDA-MB-231-b1
tumours, compared to control tumours (Figs. 3a and 3b).
Figure 4. Effect of b1 over-expression on breast cancer metastasis in vivo. At 5 weeks following implantation, control and b1 tumours were
removed post mortem prior to bioluminescent imaging. (a) Representative bioluminescent images of metastases from control and b1
tumours. (b) Bioluminescence measured from the indicated anatomical sites from control and b1 tumour-bearing mice (n5). (c) Biolumi-
nescence measured ex vivo from the spleen, liver, and lungs of control and b1 tumour-bearing mice (n5). (d) Spleen sections from con-
trol and b1 tumour-bearing mice showing GFP signal (green) and DAPI (blue). (e) GFP-positive cells per field of view of spleen (n530). (f)
Liver sections from control and b1 tumour-bearing mice showing GFP signal (green) and DAPI (blue). (g) GFP-positive cells per field of view
of liver (n530). (h) Lung sections from control and b1 tumour-bearing mice showing GFP signal and DAPI (blue). (i) GFP-positive cells per
field of view of lung (n530). Bars are mean1SEM; *p<0.05; ***p<0.001. Scale bar, 100 mm.
C
an
ce
r
C
el
l
B
io
lo
gy
8 SCN1B, breast tumour growth and metastasis
Int. J. Cancer: 00, 00–00 (2014) VC 2014 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
However, the density of apoptotic cells expressing activated
caspase-3 was signiﬁcantly reduced by 84% in MDA-MB-
231-b1 tumours, compared to control tumours (p< 0.001;
Figs. 3c and 3d). In vitro, staurosporine-induced apoptosis
was signiﬁcantly reduced in MDA-MB-231-b1 cells, com-
pared to control MDA-MB-231 cells (Figs. 3e and 3f),
Figure 5. Effect of b1 on process outgrowth in breast cancer cells. (a) Regions of skeletal muscle infiltration in control (i,iii,v) and b1
(ii,iv,vi) tumour sections showing GFP signal (green) and skeletal fast myosin (red). Arrows indicate cells in b1 tumours that have more
elongate processes. Scale bar, 50 mm. Insets, higher magnification images of tumour cells showing processes. Inset scale bar, 10 mm. (b)
Process length (mm) of control MDA-MB-231 and MDA-MB-231-b1 cells in tumours (n134 cells/each). (c) Length (mm) of muscle fibers in
control and b1 tumours (n79). (d) Images of MDA-MB-231 and MDA-MB-231-b1 cells grown on control or b1-expressing CHL fibroblast
monolayers, and stained with anti-GFP antibody. Scale bar, 20 mm. (e) Process length (mm) of MDA-MB-231 and MDA-MB-231-b1 cells
grown on control or b1-expressing CHL monolayers (n5300). (f) Process length (mm) of MDA-MB-231-b1D40–124 and MDA-MB-231-b1 cells
grown on control or b1-expressing CHL monolayers (n5300). (g) Process length (mm) of MDA-MB-231 cells grown on control or b1-
expressing CHL monolayers630 mM TTX (n144). (h) Process length (mm) of MDA-MB-231-b1 cells grown on control or b1-expressing CHL
monolayers630 mM TTX (n5150). Bars are mean1SEM; ***p<0.001.
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suggesting, together with the tumour data, that b1 over-
expression enhances resistance to apoptosis. Finally, the den-
sity of vascular structures, revealed by labelling blood vessels
with an antibody to the endothelial marker CD31, signiﬁ-
cantly increased by 1.5-fold in MDA-MB-231-b1 tumours,
compared to control tumours, and VEGF secretion in vitro
was signiﬁcantly higher in MDA-MB-231-b1 cells than con-
trol MDA-MB-231 cells (p< 0.01; Figs. 3g23i). In summary,
Figure 6. A mechanism for b1-mediated process outgrowth and migration in BCa cells. (a) Images of MDA-MB-231 and MDA-MB-231-b1
cells. Green: anti-b1 for parental MDA-MB-231 (with Alexa-488-conjugated secondary antibody) and GFP signal for MDA-MB-231-b1; red:
anti-fyn; magenta: phalloidin to label the actin cytoskeleton; blue: DAPI to label nucleus. White boxes indicate locations of inset zoomed
images. Phalloidin is omitted from merged image for clarity. Scale bar, 10 mm. (b) Intensity correlation-quotients (ICQ) for b1 and fyn in
MDA-MB-231 and MDA-MB-231-b1 cells (n520/each). (c) Process length (mm) of MDA-MB-231 cells grown on control or b1-expressing CHL
monolayers65 mM PP2 (n147). (d) Process length (mm) of MDA-MB-231-b1 cells grown on control or b1-expressing CHL monolayers65
mM PP2 (n223). (e) Process length (mm) of MDA-MB-231 cells grown on control or b1-expressing CHL monolayers6 fyn siRNA (n5150).
(f) Process length (mm) of MDA-MB-231-b1 cells grown on control or b1-expressing CHL monolayers6 fyn siRNA (n5150). (g) A model of
possible signalling mechanism underlying b1-mediated process outgrowth in BCa cells. b1 from an adjacent fibroblast or cancer cell inter-
acts in trans with b1 on the BCa cell, initiating a signaling cascade via fyn kinase, leading to process outgrowth.15 Na1 conductance
through the pore-forming a subunit is also required.16 Figure was produced using Science Slides software. Bars are mean1SEM;
***p<0.001.
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these data suggest that b1 over-expression increased the
growth of MDA-MB-231 tumours, not by altering the density
of cycling cells in the population, but, instead by reducing
apoptosis and enhancing angiogenesis.
b1 potentiates metastasis to liver and lungs
We monitored metastasis after 5 weeks by bioluminescent
imaging following post mortem resection of primary tumours
(Fig. 4a). Although photon ﬂux was slightly increased in
mice bearing MDA-MB-231-b1 tumours compared those
bearing MDA-MB-231 tumours, and in the liver and lungs
ex vivo, this difference was not statistically signiﬁcant (Figs.
4b and 4c). To study metastasis to these organs in more
detail at the cellular level, using a more sensitive method, we
measured the density of GFP-expressing tumour cells within
tissue sections. We detected GFP1 cells in sections both in
isolation, and in multicellular foci (Figs. 4d, 4f, and 4h). GFP
was co-expressed in cells with HNA (Fig. S3e). HNA is pres-
ent in human MDA-MB-231 cells, but absent in mouse cells,
thus conﬁrming that GFP expression was retained in the
tumour cells once they had metastasized. In the spleen, the
number of GFP1 cells per ﬁeld of view was unchanged
between groups (Fig. 4e). However, the number of GFP1
cells per ﬁeld of view was signiﬁcantly increased, by 5.9- and
3.0-fold, respectively, in the liver and lungs of MDA-MB-
231-b1 tumour-bearing mice, compared to control (p< 0.05
and 0.001, respectively; Figs. 4g and 4i). Thus, b1 over-
expression promoted metastasis to the liver and lungs, but
not the spleen.
b1 promotes process outgrowth
Enhancement of protrusions, e.g., pseudopodia, from cells is
associated with increased motility in 3D cultures, invasion,
and metastasis.35–37 Over-expression of b1 in MDA-MB-231
cells increases the length of processes protruding from the
cell body in vitro.24 We therefore postulated that b1 might
regulate cellular morphology in our tumour model. In the
periphery of tumour sections, MDA-MB-231-b1 cells inﬁl-
trating surrounding skeletal muscle appeared more densely
packed, and had a more elongate morphology than MDA-
MB-231 cells (Fig. 5a). In these sections, processes extending
from MDA-MB-231-b1 cells were signiﬁcantly longer than
processes on MDA-MB-231 cells (Fig. 5b). The length of
muscle ﬁbers was unchanged between tumour types (Fig. 5c).
In the nervous system, b1 regulates neuronal morphology
and neurite outgrowth via trans-homophilic adhesion.15 We
therefore set out to test the hypothesis that this neuronal
function of b1 is recapitulated when it is expressed in BCa
cells, enhancing process outgrowth. We examined the mor-
phology of BCa cells plated on monolayers of control and
b1-expressing CHL ﬁbroblasts. CHL cells were chosen
because they do not express endogenous b subunits.14 When
plated on CHL cells, MDA-MB-231 cells produced thin proc-
esses with foci at the tips, morphologically similar to neurites
with growth cones (Fig. 5d).15 MDA-MB-231 cells did not
show any increase in process length when grown on b1-
expressing monolayers (Fig. 5e). However, MDA-MB-231-b1
cells did respond, such that b1-expressing monolayers
increased process length by 1.6-fold (p< 0.001; Fig. 5e). A
similar result was observed for MCF-7 cells, which express
endogenous b1 (Supporting Information Fig. S4a and S4b).
There was no increase in process length of MDA-MB-231
cells over-expressing the Ig domain-deﬁcient mutant b1D40–
124 when grown on b1-expressing monolayers (Fig. 5f), sug-
gesting that the adhesion domain is required for b1-mediated
process outgrowth. In cerebellar granule neurons, b1-
mediated neurite outgrowth requires the presence of Nav1.6
and is inhibited by the VGSC pore-blocking toxin TTX.16
We found that TTX (30 mM) inhibited b1-mediated process
outgrowth in MDA-MB-231-b1 cells (p< 0.001; Fig. 5h).
However, it had no effect on process outgrowth in native
MDA-MB-231 cells, which do not respond to b1-expressing
ﬁbroblasts (Fig. 5g). Together, these data suggest that b1
enhances process outgrowth on BCa cells via trans-homo-
philic adhesion between b1 expressed on the BCa cell, and
b1 expressed on the adjacent ﬁbroblast, similar to its func-
tion in neurons.14
b1-mediated process outgrowth requires fyn kinase
In neurons, b1 increases neurite length via fyn kinase.15
CAM-mediated activation of fyn kinase is proposed to initi-
ate the fyn-focal adhesion kinase (FAK) pathway, activating
extracellular signal-regulated kinase 1/2, leading to neurite
outgrowth.38 Fyn is upregulated in a number of cancers,
where it contributes to an invasive phenotype.39 We found
that fyn, like b1, was expressed in MCF-10A cells and BCa
cell lines (Fig. 1g and 1h, Supporting Information Fig. S2f).
Given that fyn is required for b1-mediated neurite out-
growth, and fyn and b1 are coexpressed in brain mem-
branes,15 we hypothesized that fyn and b1 may colocalize in
BCa cells. In MDA-MB-231 and MDA-MB-231-b1 cells, b1
was expressed throughout the cytoplasm, on perinuclear
internal membranes and lamellipodia (Fig. 6a), consistent
with previous observations, although the expression of b1
was clearly lower in the former.23 Importantly, fyn showed a
broadly similar distribution to b1, with expression strongest
on F-actin-rich lamellipodia. Intensity correlation analysis
gave ICQ values >0, indicating that the signals for b1 and
fyn varied together30 (Fig. 6b). This result is consistent with
b1 colocalizing with fyn.
We next investigated whether fyn activity is involved in
b1-mediated process outgrowth in BCa cells. Inclusion of the
src family kinase inhibitor PP2 (5 mM) in the assay inhibited
b1-mediated process outgrowth in MDA-MB-231-b1 cells
(p< 0.001; Fig. 6d). However, it had no effect on process out-
growth in control MDA-MB-231 cells, which do not respond
to b1-expressing ﬁbroblasts (Fig. 6c). Importantly, 5 mM PP2
had no effect on cellular viability or proliferation (Supporting
Information Figs. S5a and S5b). To establish whether fyn is
speciﬁcally required for b1-mediated process outgrowth in
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BCa cells over other members of the src family that are also
inhibited by PP2, we next transiently down-regulated the
expression of fyn in BCa cells using siRNA, prior to plating
on ﬁbroblast monolayers (Supporting Information Fig. S5d).
Down-regulation of fyn with siRNA abrogated b1-mediated
process outgrowth in MDA-MB-231-b1 cells (p< 0.001; Fig.
6f). However, there was no effect on baseline process out-
growth in control MDA-MB-231 cells (Fig. 6e). PP2 and fyn
siRNA also inhibited b1-mediated process outgrowth in
MCF-7 cells (Supporting Information Figs. S4c and S4d). In
summary, blocking fyn expression/activity with PP2 or
siRNA inhibited b1-mediated process outgrowth in BCa cells.
These data suggest that fyn is a critical signalling intermedi-
ary in the mechanism underlying b1-mediated process out-
growth in BCa cells (Fig. 6g), as it is in neurons.15
Discussion
VGSCs are expressed in cells from a number of different can-
cers, where they are proposed to play a role in potentiating
metastasis.18 VGSCs are unique among ion channels in that
their “auxiliary” b subunits not only modulate channel activ-
ity, but are also CAMs.5 Expression of b subunits has been
reported in breast, bone, cervical, colorectal, lung, and pros-
tate cancer cell lines, and b1 is the dominant isoform in
breast, cervical, lung and prostate cancer cell lines (reviewed
in Ref. 19). However, in vivo evidence for b subunit expres-
sion in cancer is limited. We found that b1 was up-regulated
at mRNA and protein level in BCa specimens compared with
non-cancer tissue. Similarly, b1 was expressed across a panel
of BCa cell lines, although the relative mRNA and protein
levels differed. In addition, in tumour specimens, the positive
relationship between SCN1B mRNA and ER status was not
reﬂected at the protein level. Discrepancy between mRNA
and protein levels has been reported previously for other
VGSCs in other tissues.24,40,41 Therefore, the relationship
between SCN1B mRNA and b1 protein levels may be subject
to complex regulation, highlighting the critical importance of
studying biomarker expression at both mRNA and protein
levels. We did not observe a relationship between b1 expres-
sion and outcome in patient tumour specimens. This may be
due to the relatively small size of the dataset, and it would be
worthwhile in the future to validate the data presented here
against larger cohorts. In conclusion, our data show that
SCN1B/b1 is up-regulated at the mRNA and protein level in
BCa. We propose that b1 warrants further study as a poten-
tial biomarker for BCa.
b1 over-expression increased tumour growth in vivo.
Interestingly, this contrasts with the observation that over-
expression of b1 slightly reduces proliferation in vitro,24 sug-
gesting that the tumour microenvironment might be critical
to the in vivo tumour-promoting function of b1. In support
of this, apoptosis was reduced in MDA-MB-231-b1 tumours,
which may account for their increased size. Cell adhesion can
promote apoptosis suppression in cancer cells via FAK acti-
vation42 and further work is required to establish whether or
not b1-dependent adhesion promotes tumour cell survival.
There was increased density of vascular structures in the b1
over-expressing tumours, and VEGF secretion was increased
in MDA-MB-231-b1 cells in vitro, suggesting that b1 may
enhance angiogenesis. Several classes of CAMs are known to
promote angiogenesis, including integrins, cadherins, and
immunoglobulin superfamily CAMs,43 raising the possibility
that b1 may contribute to promoting blood vessel develop-
ment through heterophilic adhesion. Interestingly, over-
expression of b2 in prostate cancer cells has the reverse
effect, reducing tumour growth.44 Despite its structural simi-
larity to b1, b2 appears to play a different role in the CNS,
and is not essential for postnatal development.5 Thus, as in
the CNS, different b subunits may perform distinct functions
in different cancer microenvironments.
b1 is a multifunctional molecule that plays a critical role
during CNS development.5 Although b1 is essential for regu-
lating excitability through ﬁne-tuning VGSC gating and
kinetics,16 its function as a CAM is required for neurite out-
growth, migration, fasciculation and synaptic connectivity.15–17
In fact, b1 may function as a CAM, independent of channel
activity under certain conditions.5 Other CAMs that regulate
neuronal migration and pathﬁnding have been reported in
tumours, where they play a pathological role and associate
with poor prognosis.45 It is therefore not unreasonable to
expect that b1 may do the same. We showed previously that
b1 enhances cell-cell adhesion and cell-substrate adhesion in
BCa cells in vitro.24 In the present study, we found that b1
over-expression in MDA-MB-231 cells caused a more elon-
gate cellular morphology within tumours, and enhanced
process outgrowth in vitro via trans-homophilic adhesion.
b1-mediated process outgrowth did not occur in control
MDA-MB-231 cells, which express a low level of endogenous
b1. The latter result suggests that b1 expression on the
tumour cell may need to be above a threshold in order to
induce process outgrowth and enhance tumour growth and
metastasis. We found that, as in neurons,15 b1-mediated pro-
cess outgrowth in BCa cells required fyn kinase. b1-mediated
neurite outgrowth in neurons is also activity-dependent.16
Interestingly, Na1 current promotes src family kinase activity
and pro-invasive morphology in MDA-MB-231 cells,46 which
ﬁts with other data showing that a subunits potentiate the
invasiveness of BCa cells.20–22,46,47 We found that TTX inhib-
ited b1-mediated process outgrowth in MDA-MB-231-b1
cells, suggesting that, as in neurons,16 a subunit function is
required (Fig. 6g). Thus, Nav1.5 and b1 may both promote
mesenchymal-like elongate morphology in BCa cells, via a
combination of Na1 current and adhesion.
Our data suggest that b1 can enhance tumour growth and
metastasis via a trans-homophilic adhesion mechanism that
enhances process outgrowth on metastatic tumour cells, ena-
bling their dissemination from the primary tumour and into
surrounding tissues. This would ﬁt with the observation that
outgrowth of processes, e.g., pseudopodia, from cancer cells
increases motility, invasion, and metastasis.35–37 Thus, b1
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may be involved in collective cell migration and invasion
during tumour spreading,48,49 similar to its role in pathﬁnd-
ing and fasciculation during CNS development.15,17 However,
we do not yet know whether b1 interactions in trans occur
between adjacent tumour cells, or between tumour cells and
stromal cells, or both. Further complexity is added by the
possibility that b1 may interact heterophilically with other
CAMs,9–12 and/or extracellular matrix proteins13 present in
the tumour microenvironment, dependent on cell types/status
within the tumour.
Our data support the hypothesis that SCN1B/b1 recapitu-
lates its neurodevelopmental role to promote breast tumour
growth and metastasis. This ﬁts with a growing body of evi-
dence implicating VGSCs as mediators of an invasive/meta-
static phenotype.19 Up-regulation of genes, e.g. SCN1B,
required for normal migration and invasion processes during
development, may represent a critical event in the progres-
sion towards metastasis.50 We therefore propose that (i) b1
may represent a novel biomarker during disease develop-
ment, and (ii) targeting b1-mediated adhesion interactions
may have potential as novel anti-cancer therapy.
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